Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes

Conclusion: There was high concordance for the IHC markers: ER, PR, HER2/neu, p53, and Ki67 expression in matched pairs of PBC and corresponding synchronous MALN. However, the discordance noted in small subgroups cannot be overlooked. Thus, there is a need to perform ER, PR, HER2/neu, p53, and Ki67 IHC studies routinely in both PBC and MALN to help design therapies that are tailored to target the specific tumor clones and render maximum benefit to patients.

Source: Indian Journal of Cancer - May 17, 2020 Category: Cancer & Oncology Authors: Tejal Abasaheb Khande Avinash R Joshi Siddhi Gaurish Sinai Khandeparkar Maithili M Kulkarni Bageshri P Gogate Aniket R Kakade Piyush D Sahu Chaitnya D Khillare Source Type: research